359 related articles for article (PubMed ID: 23468081)
21. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
22. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
[TBL] [Abstract][Full Text] [Related]
23. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Patnaik A; Wood D; Tolcher AW; Hamilton M; Kreisberg JI; Hammond LA; Schwartz G; Beeram M; Hidalgo M; Mita MM; Wolf J; Nadler P; Rowinsky EK
Clin Cancer Res; 2006 Dec; 12(24):7406-13. PubMed ID: 17189413
[TBL] [Abstract][Full Text] [Related]
24. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
Leong S; Cohen RB; Gustafson DL; Langer CJ; Camidge DR; Padavic K; Gore L; Smith M; Chow LQ; von Mehren M; O'Bryant C; Hariharan S; Diab S; Fox NL; Miceli R; Eckhardt SG
J Clin Oncol; 2009 Sep; 27(26):4413-21. PubMed ID: 19652058
[TBL] [Abstract][Full Text] [Related]
25. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
Lara PN; Frankel P; Mack PC; Gumerlock PH; Galvin I; Martel CL; Longmate J; Doroshow JH; Lenz HJ; Lau DH; Gandara DR
Clin Cancer Res; 2003 Oct; 9(12):4356-62. PubMed ID: 14555506
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
Yanagitani N; Tsuchiya S; Kaira K; Sunaga N; Tsuchiya Y; Sato K; Watanabe S; Nomura S; Sakai S; Saito R; Mori M
Am J Clin Oncol; 2007 Oct; 30(5):487-91. PubMed ID: 17921708
[TBL] [Abstract][Full Text] [Related]
27. Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Wheler J; Mutch D; Lager J; Castell C; Liu L; Jiang J; Traynor AM
Oncologist; 2017 Apr; 22(4):377-e37. PubMed ID: 28275119
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
Bailey HH; Alberti DB; Thomas JP; Mulkerin DL; Binger KA; Gottardis MM; Martell RE; Wilding G
Clin Cancer Res; 2007 Jun; 13(12):3623-9. PubMed ID: 17510207
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT
Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
Laurie SA; Gauthier I; Arnold A; Shepherd FA; Ellis PM; Chen E; Goss G; Powers J; Walsh W; Tu D; Robertson J; Puchalski TA; Seymour L
J Clin Oncol; 2008 Apr; 26(11):1871-8. PubMed ID: 18398152
[TBL] [Abstract][Full Text] [Related]
32. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
[TBL] [Abstract][Full Text] [Related]
33. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
Ramalingam SS; Parise RA; Ramanathan RK; Lagattuta TF; Musguire LA; Stoller RG; Potter DM; Argiris AE; Zwiebel JA; Egorin MJ; Belani CP
Clin Cancer Res; 2007 Jun; 13(12):3605-10. PubMed ID: 17510206
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
Czito BG; Cohen DP; Kelsey CR; Lockhart AC; Bendell JC; Willett CG; Petros WP; D'Amico TA; Truax R; Hurwitz HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1066-72. PubMed ID: 17881149
[TBL] [Abstract][Full Text] [Related]
35. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
36. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.
Nemunaitis J; Cunningham C; Senzer N; Gray M; Oldham F; Pippen J; Mennel R; Eisenfeld A
Cancer Invest; 2005; 23(8):671-6. PubMed ID: 16377585
[TBL] [Abstract][Full Text] [Related]
38. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
Fabi A; Barduagni M; Ferraresi V; Cortesi E; Gamucci T; De Marinis F; Saltarelli R; Gabriele A; Pellicciotta M; Ceribelli A; De Marco S; Facciolo F; Cognetti F
J Exp Clin Cancer Res; 2004 Mar; 23(1):25-32. PubMed ID: 15149147
[TBL] [Abstract][Full Text] [Related]
39. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
[TBL] [Abstract][Full Text] [Related]
40. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]